ANTIBODY RESPONSES AND SAFETY OF THE COMMERCIALLY AVAILABLE VACCINES AGAINST SARS-COV-2 VIRUS IN ALLOGRAFTED PATIENTS: REAL WORLD DATA FROM A SINGLE CENTER Panayotis Kaloyannidis; Belal Blowi; Rana Yahya; Hamdah Al Khaldi; Rabab Attas; Afra Dayel; Solaf Kanfar;

Risk assessment for newly diagnosed, fit and young patients with Multiple Myeloma, in the era of novel treatment modalities: Are there any additional factors to be under consideration? Panayotis Kaloyannidis; Fatema Abdulla; Enas Mutahar; Haidar Hashim; Salman Harbi; Analie Estanislao; Solaf Ka;